Dennis S. Charney, MD, is Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs for the Mount Sinai Health System. Charney is a world expert in the neurobiology and treatment of mood and anxiety disorders, making fundamental contributions to the understanding of the causes of human anxiety, fear, and depression, and the discovery of new treatment for mood and anxiety disorders. His research on depression has led to discovery of new and novel therapies for treatment resistant depression including Ketamine and the first digital treatment for depression (EFMT). He has been honored with all of the major awards in his field for his scientific research, including World’s Most Influential Scientific Minds 2014 and 2015, Ranked 48 out of 1,360 of Most Highly Cited Life Science Researchers in the World. His discovery for Ketamine for Treatment-Resistant Depression was named by Cleveland Clinic on its Top 10 list of 2017 Health Care Innovations. He holds 3 U.S. Patents, and 19 U.S. and Foreign Patent Applications, 10 of which are licensed to 2 companies. He has published 785 articles and book chapters, and 16 books, including Resilience: The Science of Mastering Life’s Greatest Challenges, and Charney & Nestler’s Neurobiology of Mental Illness 5th Edition. Charney was elected to the National Academy of Medicine in 2000, and the National Academy of Inventors in 2017.